Home/Pipeline/AB-4000 Series (with BMS)

AB-4000 Series (with BMS)

Solid Tumors

Discovery/PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Discovery/Preclinical

Status

Active

Company

Arsenal Biosciences

About Arsenal Biosciences

Arsenal Biosciences is a private, clinical-stage biotechnology company founded in 2019 and headquartered in South San Francisco, California. The company is developing next-generation, programmable T cell therapies for solid tumors, leveraging a proprietary technology platform that integrates synthetic biology and computational tools. ArsenalBio has established a strategic multi-program collaboration with Bristol Myers Squibb and is advancing a wholly owned pipeline, with its lead candidate, AB-3028 for prostate cancer, anticipated to enter First-in-Human trials in the first half of 2026. The company is led by a seasoned team with deep expertise in cell therapy, oncology, and company building.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed